Patents Examined by Patricia Duffy
  • Patent number: 9782354
    Abstract: An oral enteric delivery system includes an outer shell assembled from multiple solid shell segments joined together by a binder. The binder does not dissolve upon exposure to the gastric environment, but it dissolves in the upper small intestine, causing the shell to disintegrate and causing the payload contained within the shell to be released in the digestive tube downstream of the stomach.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: October 10, 2017
    Inventors: Grant Rufus Sparling, II, Taha Basim Al-Jishi, Vishal Prasanth Babu, Sondus Mohammad Towfik Bellow, Somee Park, Krisha Jay Patel, Rod Rodjanapiches, Vigne Sridharan, Lisa Tang, Rameez Moez Badrudin Visram Virji
  • Patent number: 9775807
    Abstract: The invention relates to solid medicinal forms containing at least one active ingredient and at least one pharmaceutically compatible, water soluble drying agent which is selected from the group consisting of trimagnesium dicitrate and/or calcium chloride, the solid medicinal form having a drying loss of at most 6% and a relative equilibrium moisture content of 25% or less. The invention also relates to solid medicinal forms containing a moisture-sensitive active ingredient and trimagnesium dicitrate.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: October 3, 2017
    Assignee: Losan Pharma GmbH
    Inventors: Peter Gruber, Dirk Spickermann
  • Patent number: 9730995
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: August 15, 2017
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • Patent number: 9730993
    Abstract: The present invention provides methods and systems for targeted delivery of a compound to a target cell that over-expresses two different proteinases. Specifically, two different modified protective antigen proteins, each comprising a cleavage site recognized by a distinct proteinase in place of the native proteinase cleavage site recognized by furin, are administered in combination with a compound that contains a protective antigen binding site. Upon cleavage by the two proteinases the two modified protective antigen proteins form a hetero-oligomer, allowing the compound to bind to the hetero-oligomer and subsequently to be translocated into the target cell.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: August 15, 2017
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Clinton Edward Leysath, Stephen H Leppla, Damilola Daniel Phillips
  • Patent number: 9726673
    Abstract: The present invention relates to novel methods for treating diseases and monitoring B cell levels in subjects and kit and compositions relating thereto by measuring serum BAFF levels in the subjects.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: August 8, 2017
    Assignee: Genentech, Inc.
    Inventor: Flavius Martin
  • Patent number: 9708434
    Abstract: Thermoplastic elastomer compositions are described comprising multigraft copolymers. The multigraft copolymers can comprise a rubbery polymeric backbone and a plurality of glassy polymeric side chains, each attached at one of a plurality of branch points randomly spaced along the backbone. The copolymer materials have high tensile strength, high strain at break, and low residual strain after elongation. The compositions can be used as adhesives and in a wide variety of high tech, medical, and commodity applications.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: July 18, 2017
    Assignees: University of Tennessee Research Foundation, University of Massachusetts, Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e.V.
    Inventors: Jimmy W. Mays, Samuel P. Gido, Roland Weidisch, Liane Weidisch, Christina Weidisch
  • Patent number: 9694032
    Abstract: The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from soy or lentil plant material or a reactive extract thereof of the plant material. The gold nanoparticles of the invention can be fabricated with an environmentally friendly method for making biocompatible stabilized gold nanoparticles. The nanoparticles can be introduced in vivo to conduct enhanced imaging. The nanoparticles can also be introduced in vivo to conduct therapy.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: July 4, 2017
    Assignee: The Curators of University of Missouri
    Inventors: Kattesh V. Katti, Raghuraman Kannan, Kavita K. Katti, Nripen Chanda, Ravi Shukla
  • Patent number: 9678072
    Abstract: Synthetic ligand compounds and methods of differentiating between Shiga toxin 1 and Shiga toxin 2 are disclosed herein. Another embodiment includes a kit for differentiating between Shiga toxin 1 and Shiga toxin 2. Assay systems and methods for providing an assay are also provided for herein.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: June 13, 2017
    Assignee: University of Cincinnati
    Inventors: Suri Saranathan Iyer, Duane Michael Hatch, Ramesh Ratan Kale, Allison Ann Weiss, Shantini D. Gammage, Colleen McGannon O'Malley
  • Patent number: 9668987
    Abstract: Novel topical compositions for the treatment of nail and skin afflictions comprising at least one active agent, at least one volatile solvent, at least one film-forming ingredient and at least one phospholipid, processes for their preparation and methods of treatment of nail and skin afflictions. Following application of the compositions and evaporation of volatile solvents, the composition produces a film, which has web-like structures containing the active agent(s).
    Type: Grant
    Filed: August 1, 2011
    Date of Patent: June 6, 2017
    Inventor: Elka Touitou
  • Patent number: 9655957
    Abstract: A method for inducing protective immunity in a vertebrate host against malaria, by administering to the host a live rodent Plasmodium organism and exploiting its cross-species protection potential. A method to use genetically engineered live rodent Plasmodium organisms expressing antigens from different stages of the life cycle of human-infective Plasmodium species to immunize vertebrate hosts against malaria. The invention further provides for the production of a vaccine composition, by suspending wild-type or genetically modified rodent Plasmodium organisms in a suitable pharmaceutically acceptable carrier solution.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: May 23, 2017
    Inventors: Rui Miguel Prudencio Pignatelli, Maria Manuel Dias Da Mota, Antonio Manuel Barbeiro Mendes
  • Patent number: 9650430
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: May 16, 2017
    Assignee: BIOGEN, MA INC.
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • Patent number: 9642901
    Abstract: Provided are methods of selecting at least three domains of the malarial CSP protein for generating non-cross reacting neutralizing antibody immune responses to the malarial parasite which prevents an infection of a human being when bitten by a malaria infected mosquito. The method comprises priming an individual by administering a mixture of adenoviral expression vectors encoding fusion proteins or the fusion proteins themselves which comprises the malarial CSP antigen fragments linked to the extracellular domain of the CD40 ligand. The adenoviral expression vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing selected malarial sporozoite CSP antigen fragments linked to the CD40 ligand in order to block the attachment to or infection of the human liver cell(s) by the malarial sporozoite.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: May 9, 2017
    Assignee: MICROVAX, LLC
    Inventor: Albert B. Deisseroth
  • Patent number: 9636304
    Abstract: A solid oral pharmaceutical composition in the form of tablets including:—a first solid oral pharmaceutical formulation in the form of at least one micro-tablet, the micro-tablet consisting of a core including at least one Krebs cycle precursor salt as active ingredient, and of a coating including at least one coating agent, and—a second oral pharmaceutical formulation in the form of at least one mini-tablet, the mini-tablet consisting of a core including at least one bicarbonate salt as active ingredient and at least one prolonged-release matrix, and of a coating including at least one coating agent. The use thereof as a medicament, in particular in the treatment and/or prevention of cystinuria.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: May 2, 2017
    Assignee: ADVICENNE
    Inventors: Catherine Guittet, Luc-Andre Granier, Caroline Roussel-Maupetit
  • Patent number: 9616117
    Abstract: An anthrax vaccine with alhydrogel as the adjuvant is presented in a composition formulated by mixing rPA with colloidal alhydrogel (alum) adjuvant to produce the final product, comprising 200 ?g/ml rPA bound to 0.26% alhydrogel in phosphate buffered saline (PBS), said formulation containing an optimal concentration of phosphate. Methods of using the vaccines to treat or prevent infections are also presented.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: April 11, 2017
    Assignee: PharmAthene, Inc.
    Inventors: Allan Watkinson, David Woodhouse, Robert Wilson
  • Patent number: 9579370
    Abstract: Certain embodiments are directed to compositions comprising EHEC-specific antigens. In certain aspects EHEC O157:H7-specific antigen(s) are used as components of immunogenic compositions and vaccines.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: February 28, 2017
    Inventor: Alfredo G. Torres
  • Patent number: 9572812
    Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: February 21, 2017
    Inventors: Jeremy C. Wright, Wilma Tamraz, John J. Leonard, John W. Gibson, Keith E. Branham, Stefania Sjobeck, Brooks Boyd, Christopher M. Rubino
  • Patent number: 9568473
    Abstract: The present invention provides an isolated and purified heat shock protein 60 (Hsp60) peptide having the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to a vaccine against Ehrlichia comprising a peptide homologous to the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to an antibody directed against a peptide homologous to the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to a method of determining whether a subject is infected with Ehrlichia, comprising the steps of: contacting a sample from a subject with the antibody described herein; and detecting a resulting antibody reaction, wherein a positive reaction indicates the subject is infected with Ehrlichia.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: February 14, 2017
    Inventors: David H. Walker, Sunil Thomas
  • Patent number: 9567295
    Abstract: The invention relates to medicine, and specifically to synthetic biologically active derivatives of carbopentoxysulfanilic acid. The novel substance comprises a (2,6-dichlorophenyl)amide salt of carbonpentoxysulfanilic acid of general formula: wherein X is Na, K, NH4; the drug may be contained in tablets, including sublingual tablets, or in capsules, or in suppositories, or in drops, or in mixtures, or in ointments, creams or other forms for application to the skin and mucosae, or in an oral-buccal film, or in a spray, or in a liquid for parenteral administration, or in chewing gum. A preparation having pronounced activity against herpes viruses is thus produced.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: February 14, 2017
    Inventors: Viktor Veniaminovich Tets, Georgy Viktorovich Tets, Viktor Iosifovich Krutikov
  • Patent number: 9562896
    Abstract: The invention generally relates to conducting an assay on a sample that isolates a bacterium from the sample, in which the assay isolates as low as about 1 CFU/ml of bacteria in the sample.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: February 7, 2017
    Assignee: DNAE Group Holdings Limited
    Inventors: Victor C. Esch, Sergey A. Dryga, Lisa-Jo Ann Clarizia
  • Patent number: 9556441
    Abstract: Site-specific Listeria integration vectors and methods for their use are provided. The subject vectors include a bacteriophage integrase gene and a bacteriophage attachment site, where in many embodiments the bacteriophage that is the source 0 of these elements is a listeriophage. In certain embodiments, the subject vectors further include a multiple cloning site, where the multiple cloning site may further include a polypeptide coding sequence, e.g., for a heterologous antigen. The subject vectors and methods find use in a variety of different applications, including the study of Listeria species and the preparation of Listeria vaccines.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: January 31, 2017
    Inventors: Daniel A. Portnoy, Richard Lane Calendar, Peter M. Lauer